Novotech Honored with Frost & Sullivan’s 2024 Best Practices Company of the Year Award for Leadership in Biotech CRO Services
Novotech, the global full-service clinical Contract Research Organization (CRO), is proud to announce that it has been awarded the prestigious 2024 Global Company of the Year Award by Frost & Sullivan. This recognition underscores Novotech’s commitment to accelerating clinical development for biotech companies through innovative solutions, advanced analytics, and a comprehensive global reach.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910876910/en/
(Graphic: Business Wire)
Frost & Sullivan’s award honors Novotech’s innovative full-service approach that accelerates clinical development through advanced analytics, access to diverse patient populations, and through specialized technology.
“Overall, Novotech distinguishes itself in the ever-expanding CRO market by successfully addressing the complex regulatory landscape with a deep understanding of local regulations and overcoming cultural barriers to establish itself as a truly global CRO. As a result, the company progresses closer to becoming a preferred global partner with regional leadership and localized expertise,” said Unmesh Lal, Global Research Director at Frost & Sullivan.
Unmatched Global Reach and Expertise
Novotech's extensive global footprint allows the company to provide tailored solutions that address the unique regulatory and cultural nuances of each market. This strategic advantage facilitates faster patient recruitment and enhanced trial efficiency, ensuring successful outcomes for its biotech clients. Novotech's project manager-centric model ensures seamless communication and effective execution of clinical trials, fostering strong, collaborative relationships with clients.
Commitment to Innovation and Advanced Technology
A key element in being awarded this accolade is Novotech continuing to leverage cutting-edge technology to enhance clinical trial operations. The company's ongoing investments in artificial intelligence (AI), big data analytics, digital clinical trials, and cloud-based software platforms significantly improve data quality, trial planning, and transparency in communications with stakeholders. Partnerships with industry leaders like Veeva and Medidata further empower Novotech’s clients to optimize their drug development programs.
Recognition of Excellence
Frost & Sullivan first recognized Novotech with their award for best APAC CRO in 2006, and Novotech has continued to win this award every year since. Receiving, for the first time, Frost & Sullivan’s 2024 Global Company of the Year Award is tangible evidence of Novotech’s drive for constant improvement and creating optimal outcomes for our partners and clients.
“We are honored to receive the 2024 Global Company of the Year Award from Frost & Sullivan,” said Dr. John Moller, CEO of Novotech. “This recognition is a testament to the hard work and dedication of our team, our commitment to innovation, and our unwavering focus on delivering exceptional results for our biotech and pharmaceutical clients. We are proud to be at the forefront of advancing clinical development and to be acknowledged as a leader in the CRO industry.”
Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910876910/en/
Contacts
Media
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shin-Etsu Chemical Develops Industry-First Heat-Shrinkable Silicone Rubber Tubing for Busbar Covering11.9.2024 08:00:00 CEST | Press release
Shin-Etsu Chemical Co., Ltd. (TOKYO: 4063) (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed the ST-OR Type heat-shrinkable silicone rubber tubing for busbar covering for the first time in the industry*. A busbar is a conductive metallic strip, typically made of copper or aluminum, and is used for power connection or distribution. Busbars have found wide-ranging applications and grown in demand for use not only in switchboards and control panels but also in electric vehicles (EVs) and hybrid vehicles (HEVs) more recently. For being subjected to high currents and high voltages, busbars are protected with tape, tubing, or other insulating parts. In particular, busbars used in EVs and HEVs must endure even higher voltages and currents and thus require insulating parts that provide more advanced properties, including superior electrical insulation and heat resistance. The ST-OR Type heat-shrinkable silicone rubber tubing for busbar covering, whic
Tula Technology Expands DMD into China, the World’s Electrified Vehicle Market Leader11.9.2024 02:00:00 CEST | Press release
Tula Technology, Inc., a leader in propulsion efficiency, along with a leading global automotive supplier, has developed a Dynamic Motor Drive® (DMD) demonstration vehicle for the Chinese market based on a domestic premium full-size SUV. DMD is a cost-effective, software-only technology that improves electrified vehicle efficiency and addresses key challenges facing the EV transition: range, battery size, and cost. Tula’s goal with DMD is to aid the switch to electric vehicles by improving their efficiency, and also the efficiency of transitional vehicles like plug-in hybrids. The demonstration vehicle was developed around a plug-in hybrid full-size SUV, specifically a range-extended EV that includes a small internal combustion engine used only for charging the traction battery. Tula’s DMD was implemented onto the rear primary eDrive, which consisted of an Interior Permanent Magnet (IPM) motor and Insulated Gate Bipolar Transistor (IGBT) inverter. From start to finish, implementation a
Lone Star Funds Announces Final Closing of Lone Star Real Estate Fund VII10.9.2024 20:30:00 CEST | Press release
Lone Star Funds today announced the final close of its latest commercial real estate fund, Lone Star Real Estate Fund VII, L.P. (“LSREF VII”). Total capital available to LSREF VII is approximately $2.7 billion. “With the ongoing complex and changing real estate landscape, LSREF VII anticipates deep-value and special situation investment opportunities across Europe, North America and Japan,” said Donald Quintin, Chief Executive Officer of Lone Star. “Lone Star has been investing in the broader commercial real estate sector for nearly 30 years, and we believe that the current environment is likely to play to our strengths as a disciplined and flexible opportunistic investor. We greatly appreciate the continued support of our longstanding partners who have supported us again during our most recent fundraise.” LSREF VII will target opportunistic and value-add commercial real estate investments including direct commercial real estate equity, debt portfolios, and commercial real estate-relat
Applications Open for 2025 SPIE Startup Challenge10.9.2024 20:28:00 CEST | Press release
Applications are now open for the 2025 SPIE Startup Challenge. The annual entrepreneurial pitch competition is held by SPIE, the international society for optics and photonics, as part of SPIE Photonics West. In 2025, Photonics West will be held 25-30 January in San Francisco's Moscone Center, with the SPIE Startup Challenge finals being held 28 January. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910073009/en/ The winning shot at the SPIE Startup Challenge in 2024: Jenoptik’s Ralf Kuschnereit, TRAQC's Benjamin Dringoli, and 2024 SPIE President Jennifer Barton. (Photo: Business Wire) The SPIE Startup Challenge is a competitive entrepreneurial platform for new businesses that utilize optics and photonics for innovative products or applications. Participating teams compete for sponsored prizes, in addition to gaining increased visibility with potential investors. Cash prizes of $10,000, $5,000, and $2,500, provided by St
Boyd Watterson and Amber Infrastructure Finalize Strategic Combination, Establishing a Premier Global Alternatives Investment Platform10.9.2024 20:18:00 CEST | Press release
Boyd Watterson Asset Management (“Boyd Watterson”) and Amber Infrastructure Group Holdings Limited (“Amber”) announced they have completed their previously-announced strategic combination. The transaction closed on August 30 following the receipt of all necessary investor consents and regulatory approvals, including UK FCA consent. The combination creates a global diversified Real Estate, Infrastructure, and Fixed Income asset management platform with approximately $35.7 billion in AUM. The new Company, including its operating subsidiaries, is a premier global alternatives investment manager with over three-hundred investment personnel, offices in eight US cities and twelve countries. Boyd Watterson’s and Amber’s clients, partners, and employees are expected to benefit from the enhanced scale of the combined global platform underpinned by a diversified revenue base, expanded product opportunities, and enhanced investment acumen. Operating under a common parent company, Boyd Watterson L
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom